TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants aged ≥ 19 years~* Participants who have voluntarily given written consent to participate in this clinical trial~* Participants with LDL-C ≤ 250mg/dL and TG \< 500mg/dL at Visit 1~* Participants with LDL-C ≤ 250mg/dL, TG \< 500 mg/dL and satisfied criteria according to cardiovascular risk category at Visit 2 (after at least 4 weeks of TLC)~Exclusion Criteria:~* Patients with active liver disease and severe liver impairment~* Patients with severe renal failure (eGFR \< 30 mL/min/1.73 m2 at Visit 1)~* Patients with type I diabetes or uncontrolled type 2 diabetes~* Patients with acute hypertension or uncontrolled hypertension (sitSBP ≥ 180 mmHg or sitDBP ≥ 110 mmHg at Visit 1)~* Patients with symptomatic orthostatic hypotension~* Patients with NYHA class III\~IV heart failure, CCSA class III\~IV angina, ventricular arrhythmia, severe hemorrhagic or ischemic cerebrovascular diseases, transient ischemic attacks (TIAs), acute coronary syndrome or a history of angioplasty, percutaneous coronary intervention, or coronary artery bypass surgery within six months before Visit 1.~* Patients who were diagnosed with a malignant tumor within five years before Visit.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGP1910 (Type: EXPERIMENTAL): None
- HCP1903 (Type: EXPERIMENTAL): None
- HGP1909 (Type: ACTIVE_COMPARATOR): None
- HGP1911 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients who proved H. pylori infection following three methods~  * Positive rapid urease test~ * Histologic evidence of H. pylori by modified Giemsa staining~ * Positive stool Antigen Test~Exclusion Criteria:~* Patients who received eradication therapy for H. pylori infection, previously~* H. pylori eradication failure because of poor compliance~* The administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks~* Advanced gastric cancer or other malignancy~* Abnormal liver function or liver cirrhosis~* Abnormal renal function or chronic kidney disease~* Other severe concurrent diseases~* Previous allergic reactions to the study drugs~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tavanex & Nexium & Tinafas (Type: EXPERIMENTAL): Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days
- Lanzol & Klacid &Iramox (Type: ACTIVE_COMPARATOR): Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Substance Use Adaptation of Fathering Through Change

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* identify as being in recovery~* abstinent from illicit substances for at least 1 day and less than one year at time of enrollment~* parenting responsibilities for a child between the ages of 3-16~* spend at least 2 hours per week with child between ages of 3-16~* English speaking~Exclusion Criteria:~-

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): 6 weeks of Fathering Through Change videos and 3 individual coaching calls.
- Control (Type: NO_INTERVENTION): Links to parenting websites

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Above 40 years of age~2. American Society of Anesthesiologists (ASA) Physical Status I, II, III.~3. COPD diagnosed , criteria ( on preop. PFT : FEV1 \< 80%, FEV1 / FVC \< 70% after bronchodilator)~4. thoracic surgical procedure~Exclusion Criteria:~1. severe functional liver or kidney disease~2. diagnosed HF ( NYHA class \>3)~3. arrhythmia or received treatment with antiarrythmic drug .~4. exceed BMI \> 30 kg/ m2~5. bradycardia (HR \<50 bpm)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): saline solution
- dexmedetomidine group (Type: ACTIVE_COMPARATOR): dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV positive test (2 rapid diagnostics tests (RDTs) followed by a confirmatory ELISA test).~* Diagnosis of VL (first episode or relapse) confirmed by bone marrow or spleen aspirate.~* Male and female age: 18-60 years.~* Written informed consent from the patient.~Exclusion Criteria:~* Women of child-bearing potential (defined as women who have achieved menarche) who are not using an assured method of contraception or are unwilling to use an assured method of contraception for the duration of treatment and four months after.~* Pregnant women or breast-feeding mothers.~* Patients with grade 2 or 3 post kala-azar dermal leishmaniasis (PKDL) lesions.~* Clinical or biological evidence of severe cardiac, renal or hepatic impairment.~* Known hypersensitivity to AmBisome® and/or miltefosine.~* Patients receiving allopurinol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Liposomal Amphotericin B / Miltefosine (Type: EXPERIMENTAL): Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~* 1 x 50 mg capsule per day if patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg
- Liposomal Amphotericin B (Type: EXPERIMENTAL): Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluticasone Furoate on Methacholine Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* forced expiratory volume in one second (FEV1) greater than or equal to 65% predicted~* methacholine PD20 less than or equal to 400mcg~* no allergen exposure (if atopic) or respiratory infection for at least 4 weeks prior to study start~Exclusion Criteria:~* regular use of inhaled corticosteroid within 4 weeks of study start~* poorly controlled asthma~* current smoker or ex smoker with greater than 10 pack year history~* pregnancy or breast-feeding~* health concern/condition that would preclude participation for safety reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate (Type: EXPERIMENTAL): Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints
- Matching Placebo (Type: PLACEBO_COMPARATOR): Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight and/or obese men and women with a body mass index (BMI) 30 to 45 kg/m2 with or without a comorbid condition (e.g., hypertension, dyslipidemia, CV disease, glucose intolerance, sleep apnea), or 27 to 29.9 kg/m2 with at least one comorbid condition.~* Ability to complete a 1 year study~Exclusion Criteria:~* Pregnancy~* Diabetes mellitus (type I, II or other)~* History of symptomatic heart valve disease~* Serious or unstable current or past medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lorcaserin 10 mg QD (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and placebo tablet each evening
- Lorcaserin 10 mg BID (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and evening
- Matching Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet each morning and evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for inclusion in this study have to fulfill all of the following criteria:~  1. Written informed consent must be obtained before any assessment is performed.~ 2. Patients who complete the treatment epoch in study CQGE031C2201 and complete at least Visit 203 (Week 32 of the follow-up epoch, ≥16 weeks after last injection) and present with active disease as defined by UAS7 ≥12.~ 3. Patients must not have any missing eDiary entries in the 7 days prior to Visit 301 (patients are allowed to repeat until this criterion is met).~ 4. Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.~Exclusion Criteria:~Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin diseases than chronic spontaneous urticaria with chronic itching~* Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine~* History of anaphylaxis~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to any of the study drugs or its components of similar chemical classes~* Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ligelizumab (Type: EXPERIMENTAL): QGE031 240 mg s.c. q4w x 13 treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, age range 18 and over.~* Patient with acute neck pain meeting baseline pain intensity level and duration~Exclusion Criteria:~* Pain medication was taken within the 6 hours that precede randomization.~* Patient with chronic neck pain as defined as pain for 3 months or longer~* Any neck pain that is attributable to any organic disease, such as prolapsed disc, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumors.~* Any recent strains of the neck muscles documented by the clinical evaluation and anamnesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclofenac diethylamine 1.16% gel (Type: EXPERIMENTAL): None
- placebo gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. AML (including secondary AML) diagnosed as per WHO criteria~2. For relapsed/refractory subjects only:~   * Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction regimens, at least one containing anthracyclines~  * Medically eligible to receive MEC~  * Absolute blast count (ABC) ≤ 40,000/mm~3. For treatment-naïve subjects only:~   * Subjects ≥ 60 years of age with newly diagnosed AML~  * Medically eligible to receive 7+3 cytarabine/idarubicin~  * ABC count ≤ 40,000/mm~4. ECOG performance status 0-2~5. Hemodynamically stable and adequate organ function~Exclusion criteria:~1. Acute promyelocytic leukemia~2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)~3. Active signs or symptoms of CNS involvement by malignancy~4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing~5. Known history or evidence of active hepatitis A, B, or C or HIV~6. Uncontrolled acute life threatening bacterial, viral or fungal infection~7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring immunosuppressive therapy~8. Hematopoietic stem cell transplantation ≤ 4 months of dosing~9. Clinically significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Phase I) (Type: EXPERIMENTAL): GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
- Arm B (Phase II Arm A) (Type: EXPERIMENTAL): GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
- Arm C (Phase II Arm B) (Type: EXPERIMENTAL): GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and/or Female subjects with Hemophilia A.~* Subjects/parents/legal representatives must be able to comply with registry procedures (informed consent/assent process, clinical visits, reporting of infusion and bleed data, reporting of adverse events, etc).~* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative, parent(s)/legal guardian) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~* Presence of any other bleeding disorder in addition to hemophilia A.~* Treatment with immunomodulatory therapy (e.g., intravenous immunoglobulin, routine systemic corticosteroids, cyclosporins, anti-TNF agents) within 30 days prior to study entry or planned use for the duration of their study participation.~* Subjects with a past history of, or current factor VIII inhibitor. For laboratory-based assessments, any Bethesda inhibitor titer greater than the laboratory's normal range or ≥0.6 BU/mL.~* Subjects with known hypersensitivity to the active substance or to any of the excipients of Xyntha.~* Subjects with a known hypersensitivity to Chinese Hamster Ovary cell proteins.~* Unwilling or unable to follow the terms of the protocol.~* Any condition which may compromise the subject's ability to comply with and/or perform study-related activities or that poses a clinical contraindication to study participation (these conditions include, but are not limited to, inadequate medical history to assure study eligibility; expectation of poor compliance in provision of observations for study-related documentation), in the opinion of the Investigator.~* Participation in other studies involving investigational drug(s) (Phases 1-4) within 30 days before the current study begins and/or during study participation (exception for studies on Xyntha).~* Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous infusions of Xyntha (Type: EXPERIMENTAL): Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who receive LeFort I osteotomy of maxilla and bilateral sagittal split osteotomy of mandible~Exclusion Criteria:~* patients with local or systemic diseases~* patients taking aspirin, steroid, nonsteroidal anti-inflammatory drugs, or having contraindications for steroids~* patients with history of psychosis~* patients with active or chronic infection~* patients with active or latent peptic ulcer

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dexamethasonelow-dose (Type: ACTIVE_COMPARATOR): 5mg
- Dexamethasonehigh-dose (Type: EXPERIMENTAL): 15mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 1 month or older at screening.~2. Clinical diagnosis of CTX with biochemical confirmation.~3. Women of childbearing potential must agree to the use of one highly reliable method of contraception during the study, plus one additional barrier method during sexual activity.~4. Males must be surgically sterile, or males and their sexual partners must together agree to use medically accepted methods of contraception that are considered highly reliable during the course of the study.~Exclusion Criteria:~1. Genetic testing does not confirm CTX.~2. Malabsorption disorder or confounding inflammatory gastrointestinal condition (for example, irritable bowel syndrome).~3. Documented history of heart failure.~4. Treated with medications which impact bile acid absorption such as bile acid sequestering agents (eg, cholestyramine, colestipol, aluminum-based antacids.~5. Treated with cholic acid medication.~6. Female patient who is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.~7. Positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B infection or hepatitis C infection.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult Cohort (Type: EXPERIMENTAL): Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
- Pediatric Cohort (Type: EXPERIMENTAL): Pediatric cohort patients (≥1 month and \<16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete